May 12 (Reuters) - British drugmaker GSK Plc said on Friday that preliminary data from a late-stage trial
showed that its experimental combination meningococcal vaccine
was effective in individuals aged 10 to 25 years.
(Reporting by Prerna Bedi and Eva Mathews in Bengaluru; Editing
by Savio D'Souza)
Disclaimer: The views expressed in this article are those of the author and may not reflect those of Kitco Metals Inc. The author has made every effort to ensure accuracy of information provided; however, neither Kitco Metals Inc. nor the author can guarantee such accuracy. This article is strictly for informational purposes only. It is not a solicitation to make any exchange in commodities, securities or other financial instruments. Kitco Metals Inc. and the author of this article do not accept culpability for losses and/ or damages arising from the use of this publication.